- Conditions
- Pulmonary Hypertension
- Interventions
- Hymecromone (H01), Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Hymecromone
- Drug
- Lead sponsor
- Aparna Goel
- Other
- Eligibility
- 14 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Redwood City, California • Stanford, California
- Conditions
- Healthy, Respiratory Disease
- Interventions
- hymecromone
- Drug
- Lead sponsor
- Paul Bollyky
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Chronic Hepatitis C, Chronic Hepatitis B
- Interventions
- 4-Methylumbelliferone (Heparvit®)
- Drug
- Lead sponsor
- MTmedical Institute of Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial
- Interventions
- hymecromone
- Drug
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina